欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (2): 225-229.

• 综述与讲座 • 上一篇    下一篇

醛糖还原酶及其遗传多态性与糖尿病慢性并发症的相关性

程欢莲, 欧阳冬生   

  1. 中南大学临床药理研究所, 长沙410078, 湖南
  • 收稿日期:2009-01-20 修回日期:2009-02-05 出版日期:2009-02-26 发布日期:2020-10-30
  • 通讯作者: 欧阳冬生, 男, 博士, 硕导, 主要从事临床药理学和中药现代化研究。Tel:0731-4805380  E-mail:ouyangyj@163.com
  • 作者简介:程欢莲, 女, 硕士研究生, 主要从事临床药理学研究。Tel:13975846510  E-mail:cheng5049@163.com

Association of aldose reductase and its genetic polymorphisms with diabetic chronic complications

CHENG Huan-lian, OUYANG Dong-sheng   

  1. Institute of Clinical Pharmacology, Central South University, Changsha 410078, Hunan, China
  • Received:2009-01-20 Revised:2009-02-05 Online:2009-02-26 Published:2020-10-30

摘要: 糖尿病慢性并发症(DCC) 严重危害人类健康, 是糖尿病致残、致死的主要原因。醛糖还原酶———多元醇代谢通路的限速酶, 参与DCC 的发生发展。编码醛糖还原酶的基因具有多态性和种族差异, 其多态性与DCC 的易感性有关, 了解两者的关系有助于并发症的防治。

关键词: 醛糖还原酶, 糖尿病慢性并发症, 多态性

Abstract: Diabetic chronic complications (DCC) are severely harmful to the health of human, and are major causes leading to death and deformity from diabetes.Aldose reductase (AR), a rate limiting enzyme in polyol metabolic pathway, has implicated in the pathogenesis and development of DCC.The polymorphisms in AR gene are proved to be ethnic different.These polymorphisms are related to DCC susceptibility.The investigation on the polymorphisms may be helpful to prevention and therapy of DCC.

Key words: aldose reductase, diabetic chronic complication(DCC), polymorphism

中图分类号: